A daily medication can be better for some people, because it creates the daily habit of taking it at the same time every day, versus having to remember to take something once a week, says Masutto
"Women deserve to have a clinical trial specifically looking at [GLP-1 and] breast cancer risk, and a clinical trial is the only way to ensure equity in who gets the drugs." The good news is that the INSPIRE trial could begin in as little as six months, once it has sufficient funding
ICER last year recommended passage of a law allowing Medicare Part D to cover weight-loss medications
"You have GLP-1 receptor agonist, you have GIP receptor agonist, but then we're adding the pharmacology of glucagon as well," Jonsson said
Both drugs demonstrate meaningful weight loss of over 10%, which can improve or ameliorate many weight-related medical conditions, Lofton tells Fortune via email